SenesTech, Inc. 2016 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: SenesTech, Inc.
Reporting Period: Fiscal year ended December 31, 2016
Business Overview: SenesTech develops proprietary technology for managing animal pest populations through non-lethal fertility control. Its lead product, ContraPest, received U.S. EPA registration approval on August 2, 2016, for the management of rodent populations. The company is a smaller reporting company and an "emerging growth company" under the JOBS Act. As of December 31, 2016, the company had 29 employees (27 full-time, 2 part-time).
Key Financial Metrics
| Metric | 2016 | 2015 |
|---|---|---|
| Revenue | $318,000 | $241,000 |
| Net Loss | $(10,795,000) | $(18,173,000) |
| Operating Expenses | $10,834,000 | $15,886,000 |
| Cash and Cash Equivalents (Year End) | $11,826,000 | $141,000 |
| Accumulated Deficit | $(61,311,000) | $(50,357,000) |
| Stock-Based Compensation | $3,369,000 | $11,262,000 |
Note: Revenue consists primarily of licensing fees from a terminated agreement with Neogen Corporation and research grants. The company has not generated significant revenue from product sales.
Material Changes vs. Prior Period
- Regulatory Milestone: Received EPA registration approval for ContraPest in August 2016, a critical step toward commercialization not present in 2015.
- Capital Raise: Completed an Initial Public Offering (IPO) in December 2016, raising approximately $18.8 million in gross proceeds. This significantly improved liquidity, increasing cash balances from $141,000 in 2015 to $11.8 million in 2016.
- Expense Reduction: Total operating expenses decreased by approximately $5.1 million year-over-year. This was primarily driven by a $7.9 million reduction in stock-based compensation expense (from $11.3 million to $3.4 million) and a $4.5 million decrease in R&D expenses.
- Debt Restructuring: Converted significant portions of convertible notes and preferred stock into common stock in connection with the IPO, reducing interest expense and debt obligations.
Guidance, Outlook, and Risks
Outlook: Management expects to begin limited commercial sales of ContraPest in the second quarter of 2017. The company anticipates continuing to incur significant operating losses as it scales manufacturing, establishes sales infrastructure, and pursues international regulatory approvals (EU, India, Argentina).
Liquidity: Based on the $11.8 million cash balance as of December 31, 2016, management believes funds are sufficient to operate for at least the next 12 months.
Key Risks and Contingencies:
- Commercialization Risk: Success depends on market acceptance of a non-lethal alternative to traditional rodenticides and the ability to secure state-level registrations in the U.S.
- Legal Settlement: In January 2017 (subsequent to year-end), the company settled a dispute with Neogen Corporation, terminating their exclusive license agreement and agreeing to a $1.0 million payment. This liability was accrued in the 2016 financial statements.
- Supply Chain: Dependence on triptolide, a key active ingredient with limited sources. The company is pursuing bio-synthetic production methods to mitigate cost and supply risks.
- Internal Controls: The company previously identified material weaknesses in internal controls over financial reporting in 2015. While remediation steps were taken in 2016, the company has not yet fully assessed the effectiveness of its internal controls as an emerging growth company.
Investor Verification Checklist
- State Registrations: Verify the status of state-level registrations for ContraPest, as EPA approval does not automatically grant permission to sell in all 50 states.
- Neogen Settlement Impact: Confirm the cash outflow timing for the $1.0 million settlement with Neogen and assess the impact on the company's ability to license the technology in North America.
- Triptolide Sourcing: Review progress on the bio-synthetic triptolide initiative with Bioceres/INMET to ensure long-term manufacturing scalability and cost control.
- Revenue Recognition: Scrutinize the sustainability of revenue streams, noting that 2016 revenue was largely derived from a terminated licensing agreement and grants, not product sales.
- Internal Controls: Monitor future filings for the auditor's attestation on internal controls, which will be required once the company is no longer in the transition period for newly public companies.